Despite a drop in share price, the company's revenue growth ...

Despite a drop in share price, the company's revenue growth hints at a potentially brighter future. However, long term loss raises caution.

UroGen Pharma (NASDAQ:URGN Shareholders Incur Further Losses as Stock Declines 21% This Week, Taking Five-year Losses to 61%

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

2144 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

3362Followers

0Following

8153Visitors